If you liked this article you might like

Cramer's 'Mad Money' Recap: Disciplined Investors Rule
The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio
Cramer Quick Take: What's Next for Biotech?
Morning Briefing: 10 Things You Should Know